Celgene hits endpoint in psoriatic arthritis but misses in rheumatoid
This article was originally published in Scrip
Executive Summary
Celgene said on 12 July that its small-molecule phosphodiesterase 4 (PDE4) inhibitor apremilast showed statistical significance for the primary endpoint of ACR20 in the first of three pivotal Phase III clinical trials in psoriatic arthritis (PsA), but it missed the same endpoint in the first of two Phase II studies in rheumatoid arthritis (RA).
You may also be interested in...
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.
First Phase III Depression Data For Intra-Cellular’s Caplyta Exceed Expectations
With positive results from the first Phase III trial of lumateperone in major depressive disorder and a second readout expected later this quarter, the company plans a supplemental filing in late 2024.
Finance Watch: Ten IPOs So Far In 2024, But Returns To Date Are Subpar
Public Company Edition: This year’s newly public companies are trading an average of 9.7% below their IPO prices, including the two most recent debuts, Boundless Bio and Contineum. Also, Nkarta, Praxis and Nurix grossed $240m, $200m and $175m, respectively, in follow-on offerings.